Roche
Roche buys Ariosa Diagnostics
December 2, 2014Research and Development, Sales and Marketing IPF, IQuum, InterMune, Roche, ariosa, cfdna, diabetes, genia, seragon
Roche has purchased the privately-held US company Ariosa Diagnostics for an undisclosed fee as it looks to expand further into …
NICE U-turn on Roche leukaemia drug
December 2, 2014Sales and Marketing Gazyvaro, MabThera, NHS, NICE, Roche, leukaemia, obinutuzumab
NICE has reversed its decision on Roche’s chronic lymphocytic leukaemia (CLL) drug Gazyvaro only two months after rejecting the drug. …
Roche unveils plans for first Asian diagnostics plant
November 6, 2014Medical Communications, Sales and Marketing Asia-Pacific, China, Roche, asia pacific, asian, manufacturing
Roche has said it will invest 450 million Swiss francs ($468m) in the construction of a diagnostics manufacturing facility in …
Roche and Pharmacyclics agree leukaemia pact
October 17, 2014Research and Development, Sales and Marketing BMS, CLL, Cancer, Gazyva, Pharmacyclics, Roche, imbruvica, leukaemia
Pharmacyclics’s cancer drug Imbruvica will be tested in combination with Roche’s Gazyva in a new partnership announced by the firms. …
New cancer drugs escalate Roche earnings
October 16, 2014Research and Development, Sales and Marketing Cancer, Herceptin (trastuzumab), Kadcyla, Perjeta, Q3, Roche, ado-trastuzumab emtansine, pertuzumab
Roche’s sales saw solid growth in the first nine months of the year, increased by the firm’s new cancer medicines. …
Boehringer and Roche IPF drugs win FDA approval
October 16, 2014Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, FDA, IPF, InterMune, Roche, US, lung scarring, lungs, ofev
The FDA has approved both Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of the fatal lung …
Roche falls foul of NICE rules, again
October 3, 2014Medical Communications, Sales and Marketing CLL, Gazyvaro, NICE, Roche, blood cancer, oncology
Uncertainties in the data and high cost have seen NICE make an initial rejection of Roche’s new blood cancer drug …
Roche’s Perjeta sees ‘impressive’ survival rates
September 29, 2014Sales and Marketing Cancer, ESMO, Perjeta, Roche, breast, madrid
Roche’s oncology drug Perjeta combined with other medicines can help certain breast cancer patients live longer. This is according to …
Roche should be ‘shamed’ into lowering cancer drug price
September 16, 2014Medical Communications, Sales and Marketing Kadcyla, Margaret Connolly, Roche, Swiss, breast cancer, trastuzumab emtansine
A public petition to force Roche to lower the cost of its costly new breast cancer drug Kadcyla has been …
UK pharma pays out £150m in drug rebates
September 12, 2014Medical Communications, Sales and Marketing ABPI, PPRS, Roche, emms, rebate
The UK pharma industry has paid £150 million back to the government as part of its rebate to “underwrite the …
Remembering the patient in the Cancer Drugs Fund debate
September 5, 2014Medical Communications, Sales and Marketing Beating Bowel Cancer, Cancer Drugs Fund, Kadclya, Roche
Today Simon is a bowel cancer patient who is able to enjoy his weekly round of golf.After receiving the dreadful …
Google partners with AbbVie on ageing
September 4, 2014Medical Communications, Research and Development, Sales and Marketing 23andME, AbbVie, Abbott, Roche, calico, google
Google’s healthcare company Calico has signed its first pharma pact with US firm AbbVie in a deal that could be …
NICE: Cancer Drugs Fund must use our processes
September 3, 2014Medical Communications, Research and Development, Sales and Marketing CDF, Cancer, David Haslam, Kadcyla, NICE, Roche
NICE believes that the Cancer Drugs Fund should be aligned with its cost-effectiveness processes, after the government recently announced a …
Government rips up blank cheque on cancer drugs
August 28, 2014Medical Communications, Sales and Marketing Cancer Drugs Fund, Kadclya, Roche, avastin, sovaldi
Pharma has priced itself out of the Cancer Drugs Fund as the rising costs of its new oncology treatments sees …
US rivals Pfizer and Merck team up for lung cancer
August 27, 2014Medical Communications, Research and Development, Sales and Marketing Merck, NSCLC, Roche, Xalkori, melanoma, pembrolizumab
The two biggest rival US pharma firms have joined forces to help develop a new combination treatment for certain non-small …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
